Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia

Protein kinase inhibitors against malignant lymphoma

(2013) Osmond J D'Cruz et al.   EXPERT OPINION ON PHARMACOTHERAPY

Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery

(2012) S. Karve et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Early Relapse in ALL Is Identified by Time to Leukemia in NOD/SCID Mice and Is Characterized by a Gene Signature Involving Survival Pathways

(2011) Lüder Hinrich Meyer et al.   CANCER CELL

Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update

(2011) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic

(2010) Fatih M. Uckun et al.   BRITISH JOURNAL OF HAEMATOLOGY

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas

(2010) Fatih M Uckun et al.   Expert Review of Anticancer Therapy

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress

(2010) F. M. Uckun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic prospect of Syk inhibitors

(2009) Paolo Ruzza et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Protein kinase inhibitors: contributions from structure to clinical compounds

(2009) Louise N. Johnson   QUARTERLY REVIEWS OF BIOPHYSICS

In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties

(2008) Christoph le Viseur et al.   CANCER CELL

Therapeutic Nanoparticles for Drug Delivery in Cancer

(2008) K. Cho et al.   CLINICAL CANCER RESEARCH

CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL

(2008) Y Kong et al.   LEUKEMIA